anxiety supplaments

Feeling Anxiety This Winter? According to a New Survey,
You're Not Alone
Expert Offers Tips for the Nearly Half of U.S. Adults Combating the Winter
                                  Doldrums

    NORTHRIDGE, Calif., Jan. 5, 2007 The post-holiday season can
produce a feeling of fullness and warmth -- but not for all. For many, this
time is often the darkest of the year as winter has settled in for a long,
dreary stay.
Anxiety Rules!
One of the ways to fight and possibly cure anxiety is through the use of vitamin, mineral or herbal supplements.

Today's Featured Article:

Do you experience unnecessary fears with raging heartbeat and/or difficult breathing? Are you daydreaming or imagining something catastrophic to happen, have scary thoughts like seizure, heart attack? Are you often worried about your own or loved one' death or feel an impending sense of doom? Getting into panic whenever faced by new problems or new situations? Are you afraid and going crazy? Are you excessively nervous at times, have difficulty in concentrating; have stomach problems, dizziness or uncontrollable sweating? It is likely that you are suffering from anxiety disorders and getting "anxiety attacks". Anxiety All people experience fear and anxiety. Fear

Click here to read the rest of this article

In fact, a recent survey conducted by Harris Interactive(R) on
behalf of Nature Made(R) MoodPlus(R) SAM-e(1) has brought confirmation to
many U.S. adults' suspicions: winter blues are not a myth. Nearly two
thirds of U.S. adults (64 percent) agree that they are usually in a better
mood during the summer than the winter.
    Additional findings from the Nature Made MoodPlus SAM-e survey provide
further insights into this gray season including:
    * Stress Increases: About half of U.S. adults say their stress levels
       increase approaching the holiday season (53 percent).
    * Finding Comfort Helps: When adults' moods are low, many try to lift
       their spirits by spending time with friends and/or family (57 percent),
       going out (51 percent), or exercising (43 percent).
    * More Women are Affected than Men: Nearly half of women (47 percent)
       said they often experience the blues during the winter months, compared
       with 39 percent of men.
Watch the Anxiety Factor!

    What does this mean for Americans combating a case of the winter blues?
Registered dietitian Deralee Scanlon suggests that the survey findings
offer hope to those looking forward to a happier winter. "It is encouraging
to learn that about half of adults engage in healthy activities. While it
may seem more difficult to stay active during the colder months, it is
vital to our physical and mental well-being."
    For an extra boost, Deralee recommends incorporating a natural mood
lifting supplement to help lift low winter moods. S-adenosylmethionine,
better known as SAM-e, is a naturally occurring compound produced by the
body and found in all living cells. Clinical studies show a direct
correlation between low levels of SAM-e and low mood. Deralee asserts that
not all SAM-e supplements are created equally: "I personally recommend
Nature Made MoodPlus SAM-e because it is the brand used in most
American-based clinical trials."
    Deralee also advises eating mood-boosting foods during the season known
for overeating: "Certain foods, like too much saturated fat, can lower
mood, while super mood foods, such as fish rich in omega 3s, foods high in
protein and leafy green vegetables, can help combat winter blues."
Ultimately, Deralee encourages adults to make a personal goal to get plenty
of exercise, eat a well-balanced diet full of fruits and vegetables, spend
quality time with loved ones and try to get outdoors to make sure you are
getting enough sunlight.
    Deralee always recommends consulting with a health care professional
first to develop a personalized strategy for combating low moods. For more
mood-boosting tips, real life stories and information about vitamins and
supplements, visit http://www.naturemade.com/.
    To schedule an interview with Deralee Scanlon, M.S., R.D., or review
the full survey data, please email pnb@carryonpr.com.
    ABOUT PHARMAVITE
    For more than 30 years, Pharmavite has earned and maintained the trust
of pharmacists, consumers, and retailers by manufacturing high-quality
vitamins, minerals, herbs and other dietary supplements that are safe,
effective and science-based. As an industry leader, Pharmavite adheres to
manufacturing standards recommended by the United States Pharmacopeia
(USP), a not-for-profit organization that has set pharmaceutical and
dietary supplement quality standards since 1820. In addition, Pharmavite
participates in USP's Verification Program for dietary supplements. The
dietary supplement industry is regulated by the U.S. Food and Drug
Administration and the Federal Trade Commission, as well as by government
agencies in each of the 50 states.
    ABOUT HARRIS INTERACTIVE
    Harris Interactive is the 12th largest and fastest-growing market
research firm in the world. The company provides research-driven insights
and strategic advice to help its clients make more confident decisions,
which lead to measurable and enduring improvements in performance. Harris
Interactive is widely known for The Harris Poll, one of the longest
running, independent opinion polls and for pioneering online market
research methods. The company has built what it believes to be the world's
largest panel of survey respondents, the Harris Poll Online. Harris
Interactive serves clients worldwide through its United States, Europe and
Asia offices, its wholly-owned subsidiary Novatris in France and through a
global network of independent market research firms. The service bureau,
HISB, provides its market research industry clients with mixed-mode data
collection, panel development services as well as syndicated and tracking
research consultation. More information about Harris Interactive may be
obtained at http://www.harrisinteractive.com/.
    To become a member of the Harris Poll Online and be invited to
participate in online surveys, register at http://go.hpolsurveys.com/PR.
    (1) Methodology
        This survey was conducted online within the United States by Harris
        Interactive on behalf of Nature Made between October 16 and October 18
        among 2,384 adults (aged 18 and over). Figures for age, sex,
        race/ethnicity, education, region and household income were weighted
        where necessary to bring them into line with their actual proportions
        in the population. Propensity score weighting was also used to adjust
        for respondents' propensity to be online.

        With a pure probability sample of 2,384 one could say with a
        ninety-five percent probability that the overall results would have a
        sampling error of +/-3 percentage points. Sampling error for data
        based on sub-samples would be higher and would vary. However, that
        does not take other sources of error into account. This online survey
        is not based on a probability sample and therefore no theoretical
        sampling error can be calculated.

Articles
Anxiety and vitamin b12
Tikvah Therapeutics Signs Agreement to Develop
and Commercialize Compounds to Treat Anxiety-Related Disorders
D-cycloserine Technology Discovered at the Emory University School of
                                  Medicine

    ATLANTA, Feb. 13, 2007 Atlanta-based Tikvah Therapeutics,
Inc. has signed a licensing agreement with Therapade Technologies LLC, a
drug development company founded by researchers at the Emory University
School of Medicine and the College of William and Mary, for worldwide
rights to develop and commercialize D-cycloserine and related compounds for
the treatment of numerous anxiety-related disorders, including
post-traumatic stress disorder, panic disorder, social phobia, obsessive
compulsive disorder (OCD), as well as other afflictions exacerbated by
anxiety. Tikvah Therapeutics will also explore additional indications for
D-cycloserine through its own research and development efforts and the
support of further investigator initiated clinical trials.
    D-cycloserine, a NMDA receptor partial agonist, is currently approved
for other uses, but is expected to be used at a substantially lower dosage
in the treatment of anxiety disorders. Drs. Michael Davis and Kerry Ressler
of the Emory University School of Medicine and Yerkes National Primate
Research Center conducted preclinical studies that demonstrated
D-cycloserine helped reduce fears faster, leading to the eventual
disappearance, or "extinction," of the fear(1,2). Based on the results of
these preclinical studies, a clinical trial was initiated by the Emory
University School of Medicine in which acrophobic patients were given a low
dose of D-cycloserine or placebo, administered in conjunction with
psychotherapy. The results of the study showed that patients receiving
D-cycloserine required an average of 75 percent fewer psychotherapy
sessions to reach a defined clinical endpoint of fear reduction compared to
the normal course of therapy in other studies. Importantly, the patients
treated with D-cycloserine also exhibited increased self-exposure to
real-life fearful situations compared to those treated with placebo(3,4).
    Additional clinical proof of concept studies have demonstrated the
potential benefits of D-cycloserine in treating a variety of anxiety
disorders including Social Anxiety Disorder (SAD)(5) and OCD(6), amongst
others(7).
    "The use of D-cycloserine in treating anxiety disorders, such as
phobias, appears to have significant clinical implications -- namely its
potential to augment psychotherapy and enhance learning," said Dr. Harold
H. Shlevin, President and CEO of Tikvah Therapeutics, Inc. "The licensing
of these compounds fits nicely with Tikvah Therapeutic's risk reduction and
commercialization strategy."
    Tikvah Therapeutics is compiling an investigational new drug
application (IND) for D-cycloserine and expects to file the IND with the
U.S. Food and Drug Administration in 2007. Related compounds licensed as
part of the agreement with Therapade Technologies include a variety of
other modulators of the NMDA receptor and various combination products.
    "We are pleased to have licensed the D-cycloserine technology to Tikvah
Therapeutics," said Dr. Michael Davis, Co-Founder of Therapade Technologies
LLC, Robert W. Woodruff Professor in the Department of Psychiatry and
Behavioral Sciences at the Emory University School of Medicine and a
scientist in residence at the Yerkes Research Center. "The company's
experienced management team is committed to seeing this compound through
clinical development and into the hands of the millions of individuals
suffering from anxiety disorders."
    About Tikvah Therapeutics
    Tikvah Therapeutics focuses on exploring new uses for already approved
pharmaceutical compounds in which new therapeutic uses have been confirmed
in multiple, new clinical proof-of-concept studies. This strategy shortens
product development timelines -- in some cases by up to seven years -- and
substantially decreases the risk associated with the research and
development efforts. A second prong of its strategy is to focus on
specialized products with multiple stepping-stone indications and strong
patent protections for the new uses, thus helping to ensure manageable
commercial risk.
    Tikvah's pipeline includes Phase II compounds such as an agent
initially targeted to treat neurodegenerative diseases; D-cycloserine and
other NMDA receptor agonists for treatment of a variety of anxiety
disorders; and multiple other products under consideration.
    About Therapade Technologies LLC
    Therapade Technologies LLC was formed by Drs. Jason McDevitt, Michael
Davis and Kerry Ressler to pursue regulatory approval for the founders'
proprietary therapeutic methods for treating and curing anxiety disorders
and other related medical conditions(8).
    Bringing Hope to Life(SM)
    *Tikvah Therapeutics, "Bringing Hope to Life" and the above logo design
are trademarks of Tikvah Therapeutics, Inc., Atlanta, GA
    (1) Walker et al. J Neurosci. 2002 Mar 15;22(6):2343-51-
    (2) This work was supported by a grant from The National Institutes of
        Health (Number MH047840) to Dr. Davis.
    (3) Ressler et al. Arch Gen Psychiatry. 2004 Nov;61(11):1136-44
    (4) This work was supported by a venture grant from the Center for
        Behavioral Neurosciences that is supported by The National Science
        Foundation. under Agreement No. IBN-9876754
    (5) Hofmann et al. Arch Gen Psychiatry. 2006 Mar;63(3):298-304
    (6) D-Cycloserine Augmented Exposure Therapy for Obsessive Compulsive
        Disorder Matt G. Kushner, Suck Won Kim, Christopher Donahue, Paul
        Thuras, David Adson, Michael Kotlyar, Pharm.D, James McCabe , Jillian
        Peterson, and Edna B. Foa, Biological Psychiatry (In press)
    (7) Garakani et al. Mt Sinai J Med. 2006 Nov;73(7):941-9.
    (8) Dr. Davis and Dr. Ressler are entitled to royalty derived from
        Therapade Technologies LLC and Tikvah Therapeutics, Inc. from sale of
        products related to the research described here. Their financial
        interests could be affected by the outcome of this research. The terms
        of this arrangement have been reviewed and approved by Emory
        University in accordance with its conflict of interest policies.